Literature DB >> 25855586

Technical Issues Behind Molecular Monitoring in Chronic Myeloid Leukemia.

Elia Mattarucchi1, Francesco Pallotti, Rosario Casalone.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25855586     DOI： 10.1007/s40291-015-0139-2

Source DB:  PubMed          Journal:  Mol Diagn Ther        ISSN： 1177-1062            Impact factor:   4.074


× No keyword cloud information.
  9 in total

1.  Limit of blank, limit of detection and limit of quantitation.

Authors:  David A Armbruster; Terry Pry
Journal:  Clin Biochem Rev       Date:  2008-08

2.  Molecular monitoring of residual disease in chronic myeloid leukemia by genomic DNA compared with conventional mRNA analysis.

Authors:  Elia Mattarucchi; Orietta Spinelli; Alessandro Rambaldi; Francesco Pasquali; Francesco Lo Curto; Leonardo Campiotti; Giovanni Porta
Journal:  J Mol Diagn       Date:  2009-09       Impact factor: 5.568

3.  Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR.

Authors:  D M Ross; S Branford; J F Seymour; A P Schwarer; C Arthur; P A Bartley; C Slader; C Field; P Dang; R J Filshie; A K Mills; A P Grigg; J V Melo; T P Hughes
Journal:  Leukemia       Date:  2010-09-02       Impact factor: 11.528

Review 4.  Standardized definitions of molecular response in chronic myeloid leukemia.

Authors:  N C P Cross; H E White; M C Müller; G Saglio; A Hochhaus
Journal:  Leukemia       Date:  2012-04-16       Impact factor: 11.528

5.  Sensitive detection and quantification of minimal residual disease in chronic myeloid leukaemia using nested quantitative PCR for BCR-ABL DNA.

Authors:  P A Bartley; D M Ross; S Latham; M H Martin-Harris; B Budgen; V Wilczek; S Branford; T P Hughes; Alexander A Morley
Journal:  Int J Lab Hematol       Date:  2010-12       Impact factor: 2.877

6.  Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study.

Authors:  David M Ross; Susan Branford; John F Seymour; Anthony P Schwarer; Christopher Arthur; David T Yeung; Phuong Dang; Jarrad M Goyne; Cassandra Slader; Robin J Filshie; Anthony K Mills; Junia V Melo; Deborah L White; Andrew P Grigg; Timothy P Hughes
Journal:  Blood       Date:  2013-05-23       Impact factor: 22.113

Review 7.  Molecular monitoring of chronic myeloid leukemia: international standardization of BCR-ABL1 quantitation.

Authors:  ChaoJie Zhen; Y Lynn Wang
Journal:  J Mol Diagn       Date:  2013-07-20       Impact factor: 5.568

Review 8.  Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.

Authors:  Timothy Hughes; Michael Deininger; Andreas Hochhaus; Susan Branford; Jerald Radich; Jaspal Kaeda; Michele Baccarani; Jorge Cortes; Nicholas C P Cross; Brian J Druker; Jean Gabert; David Grimwade; Rüdiger Hehlmann; Suzanne Kamel-Reid; Jeffrey H Lipton; Janina Longtine; Giovanni Martinelli; Giuseppe Saglio; Simona Soverini; Wendy Stock; John M Goldman
Journal:  Blood       Date:  2006-03-07       Impact factor: 22.113

Review 9.  Concise review: cancer cells escape from oncogene addiction: understanding the mechanisms behind treatment failure for more effective targeting.

Authors:  Francesca Pellicano; Leena Mukherjee; Tessa L Holyoake
Journal:  Stem Cells       Date:  2014-06       Impact factor: 6.277
  9 in total
  2 in total

1.  Comment on: Technical Issues Behind Molecular Monitoring in Chronic Myeloid Leukemia.

Authors:  Mireille Crampe; Stephen E Langabeer
Journal:  Mol Diagn Ther       Date:  2015-08       Impact factor: 4.074

2.  Authors' Reply to Crampe and Langabeer: Technical Issues Behind Molecular Monitoring in Chronic Myeloid Leukemia.

Authors:  Elia Mattarucchi; Francesco Pallotti; Rosario Casalone
Journal:  Mol Diagn Ther       Date:  2015-08       Impact factor: 4.074
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.